Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Vishal A. Manickam
Observed names:
Vishal A Manickam,
Vishal Manickam
Institutions:
Georgia Institute of Technology,
Emory University,
The Wallace H. Coulter Department of Biomedical Engineering
Observed institutions:
Georgia Institute of Technology,
Emory University,
The Wallace H. Coulter Department of Biomedical Engineering,
GigaGen (United States),
University of California, Davis
ORCID:
0000-0002-5625-868X
Observed ORCID:
0000-0002-5625-868X
OpenAlex ID:
A5024794609
Latent, Immunosuppressive Nature of Poly(lactic- co -glycolic acid) Microparticles
2018
·
Riley P. Allen
, Amir Bolandparvaz
, et al.
·
ACS Biomaterials Science & Engineering
·
110
Generation of recombinant hyperimmune globulins from diverse B-cell repertoires
2021
·
Sheila M. Keating
, Rena A. Mizrahi
, et al.
·
Nature Biotechnology
·
32
PDF
GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2
2022
·
Rena A. Mizrahi
, Wendy Y. Lin
, et al.
·
Pathogens
·
9
PDF
Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy
2021
·
Erica L. Stone
, Kyle P. Carter
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
8
PDF
Correction to Latent, Immunosuppressive Nature of Poly(lactic-co-glycolic acid) Microparticles
2018
·
Riley P. Allen
, Amir Bolandparvaz
, et al.
·
ACS Biomaterials Science & Engineering
·
2
PDF
Abstract A32: GIGA-564, a third generation anti-CTLA-4 with minimal ability to block CTLA-4 binding to B7 ligands, has enhanced efficacy but reduced toxicity compared to ipilimumab in pre-clinical models
2022
·
Erica L Stone
, Kyle P Carter
, et al.
·
Cancer Immunology Research
·
1
Ingestible probes for breath-based monitoring of drug-metabolizing activity from the microbiome
2026
·
Vishal A. Manickam
, Carly E. Kimpling
, et al.
·
Science Advances
1389 GIGA-564 a third generation anti CTLA 4 with minimal ability to block CTLA 4 binding to B7 ligands has enhanced efficacy but reduced toxicity compared to ipilimumab in preclinical models
2022
·
Erica Stone
, Kyle Carter
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Show more works
View as search
Works count:
8
Citation count:
162
H-index:
4
I10-index:
2
Year
Topic
Type